US FTC Probes Planned Allergan-Soliton Merger

The US Federal Trade Commission has requested a second round of documents in its review of a proposed merger between aesthetics company Allergan, Inc. and device manufacturer Soliton, Inc., raising doubts as to whether the arrangement will pass muster with the anti-trust regulators.

The merger would have seen Allergan parent company AbbVie Inc. pay $550m to acquire Soliton, which makes an FDA-cleared device that uses acoustic shock waves to remove cellulite and...